Abstracts tagged "Personalized Medicine"

Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting
Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up
Eva L. Kneepkens¹, James C. Wei², Michael T. Nurmohamed^3,4, Kai-Jieh Yeo⁵, CY Chen⁶, Irene E. van der Horst-Bruinsma^1,7, Desiree van der Kleij⁸, Theo Rispens⁹, Gertjan Wolbink^3,9 and Charlotte L. M. Krieckaert³, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁵Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁶Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁷Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…
Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Eva L. Kneepkens¹, Dora pascual-Salcedo², Chamaida Plasencia³, Charlotte L. M. Krieckaert⁴, Desiree van der Kleij⁵, Michael T. Nurmohamed^4,6, Maria Teresa lópez-Casla⁷, Theo Rispens⁸ and Gertjan Wolbink^4,8, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunology unit, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Immunology, La Paz University Hospital, Madrid, Spain, ⁸Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].